Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab + Methotrexate in Early Rheumatoid Arthritis
NCT00487825Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Primary completion
- Dec 2008
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Canakinumab + Methotrexate with Methotrexate + Placebo (2 arms). Primary endpoint: American College of Rheumatology 50% Improvement at 26 weeks. Started Mar 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00487825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00487825.